This week's Fierce Biotech is brought to you by Lonza.

Whitepaper: Antibody Drug Conjugates in Oncology: How Technology Advances Can Streamline Development and Manufacturing

Antibody-drug conjugates (ADCs) are reshaping the oncology landscape, with commercial sales projected to surpass $30 billion by 2030. These breakthroughs promise enhanced efficacy, improved survival rates, and safer therapies for patients worldwide. But how are these advancements achieved? This whitepaper dives into the innovations driving the growth of ADCs, focusing on high drug-to-antibody ratio (DAR) ADCs and the expanding need for bioconjugation and payload-linker manufacturing capacity. Download now to learn about:

• The explosive growth of ADCs in oncology
• How bioconjugation innovations accelerate ADC advancements
• Lonza’s end-to-end solutions for ADC lifecycle management